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Tuberculosis (TB), the disease caused by Mycobacterium tuber-
culosis, remains a major public health problem globally. In 2014,
more than 9.6 million people are estimated to have fallen ill with
TB while 1.5 million people died of the disease [1] . The disease
is closely associated with poverty, which explains the high rates
of TB in countries or in geographic areas within countries where
poverty rates are high. The disease is also closely linked with HIV
which has been the major driver for the high rates of TB in many
countries of Sub – Saharan Africa [2–5] . TB is also associated with
other immunosuppressive states such as diabetes mellitus and to-
bacco smoking and it is currently postulated that the next wave
of the global TB epidemic will be driven by these emerging health
threats [6–8] . 
Over the last two decades treatment of TB has signiﬁcantly im-
proved and 61 million patients were successfully treated for TB
globally since 1995 [1] . However such successful treatment of TB
based on either documentation of bacteriological clearance of My-
cobacterium tuberculosis bacilli from the involved site or comple-
tion of the prescribed drug dose does not assess structural and
functional effects on the involved organ which is the hallmark
of the pathology of TB [9] . While any part of the body may be
affected by TB, pulmonary TB is the most common site of dis-
ease primarily because the Mycobacterium tuberculosis transmits
through the respiratory route. Thus TB is a major contributor to
the overall burden of lung disease in the world. It may be that the
majority of patients with pulmonary TB, the resulting structural
and functional damage is small and will not pose any signiﬁcant
long term lung health risk, however, for some patients an episode
of pulmonary TB may herald the beginning of chronic respiratory
disease and pose a signiﬁcant risk of reduced longevity despite the
“successful” treatment of their disease [10] . In this paper we ar-
gue on the importance of a programmatic approach to address the
long term complications of PTB and suggest mechanisms to pre-
vent, rapidly identify and provide appropriate long term care for
patients with post TB chronic lung disease. 
Long term complications of pulmonary TB 
Of the 6.3 million notiﬁed cases of TB that occurred in 2014,
81% had lung TB [1] . Based on recent trends in treatment out-
comes, about 86% of the new and relapse PTB cases notiﬁed
in 2014 were successfully treated. However, several studies havehttp://dx.doi.org/10.1016/j.jctube.2016.03.001 
2405-5794 emonstrated persistence of symptoms, reduced quality of life,
bnormal radiological ﬁndings and impaired pulmonary function
ests in patients successfully treated for PTB [11–14] . Pulmonary
B is associated with various long term lung complications in-
luding lung scarring (ﬁbrosis), bronchiectasis, Chronic Pulmonary
spergillosis (CPA), air way stenosis and Chronic Obstructive Pul-
onary Disease (COPD) [15] and it may even be a risk factor for
ung cancer [16] . There is however very limited data on the full
pectrum of these complications in cohorts of patients treated for
TB. For many of these complications the published literature is
ased mostly on case reports and small case series. In one such
tudy, Neeta Singh et al report on 51 multidrug resistant TB pa-
ients who were successful treated. Of these, 78% had persistent
espiratory symptoms, 98% had residual radiological sequelae, 96%
ad ventilatory defects with 66% of those with ventilatory defects
xhibiting a mixed type of ventilatory abnormality while 19% had
ure restriction and 11% had pure obstruction after completion of
reatment [17] . In a similar small prospective study among 25 pa-
ients with drug susceptible TB, the investigators observed resolu-
ion of exudative lesions and adenopathy at completion of treat-
ent while leaving permanent features that included emphyse-
atous change (36%), bronchiectasis (40%), bronchovascular distor-
ion(56%), and ﬁbrotic bands (64%). Structural and functional resid-
al changes were more common in patients with cavitary than
on-cavitary disease [18] . 
Towards the end of the days of the sanatoria treatment for TB,
igh rates of obstructive airways disease were observed in patients
xiting sanatoria. In one study as much as 62% of white men exit-
ng a sanatorium were found to have spirometric evidence of ob-
tructive airways disease [19] . Other studies have replicated these
ndings in addition to documenting restrictive and combined re-
trictive and obstructive ventilatory defects and a higher frequency
f lung function impairment with repeated episodes of lung TB
20–22] . In a study among South African miners with a history of
uberculosis, lung function impairment was identiﬁed in 18%, 27%,
nd 35% of subjects after one, two, or three episodes of the disease
21] . In a case-control study using pulmonary function tests of pa-
ients with culture-conﬁrmed pulmonary tuberculosis and a com-
arison group with latent tuberculosis infection, survivors of TB
ere 5.4 times more likely to have a decline in Forced Expiratory
olume in 1 s (FEV1) and Forced Vital Capacity (FVC) than were
ubjects with Latent Tuberculosis Infection (LTBI) after adjusting
or risk factors such as age, Body Mass Index, country of birth, gen-
er, and smoking [22] . In a population based Latin American study
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rhat investigated obstructive Lung disease in the community, the
verall prevalence of airﬂow obstruction deﬁned as FEV1/FVC ratio
ost-bronchodilator of less than 0.7 was 30.7% among those with
 history of tuberculosis, compared with 13.9% among those with-
ut this history [23] . A recent systematic review examining the re-
ationship between pulmonary TB and COPD in community based
tudies found a consistent association across the two community
ased studies identiﬁed with odds ratios ranging from 1.78 to 6.31,
etween a reported history of TB and Spirometry conﬁrmed COPD
mong people aged 40 years and above. The risk of COPD was cor-
elated to the TB incidence of the country [24] . This subject has
ecently received a lot of attention in the realm of the Burden of
ung Disease (BOLD) initiative [25,26] . Thus the experience of an
pisode or more of lung TB poses a signiﬁcant risk of obstructive,
estrictive and combined ventilatory lung defects which may be
rogressive leading to progressive deterioration of quality of life
nd early mortality. 
Bronchiectasis is deﬁned as the permanent dilatation and dis-
ortion of the airways. It is clinically characterized by persistent
ough with the production of sputum which in untreated patients
s often copious, purulent and associated with recurrent episodes
f hemoptysis. Bronchiectasis is a risk factor for community ac-
uired pneumonia. Robust studies on the incidence of post TB
ronchiectasis are unavailable, however in a review of this sub-
ect Toni Jordan et al indicated that the incidence of bronchiectasis
ost PTB was in the range of 19–65% and in etiological studies of
ronchiectasis, TB is often the most common identiﬁed cause es-
ecially in TB endemic settings [27] . The systematic review con-
ucted by Byrne Al et al found a signiﬁcant association between
ung TB and bronchiectasis [24] . 
Aspergillus lung disease may present in three ways: invasive
spergillosis, a serious life threatening lung disease that presents
s severe pneumonia; Allergic Bronchopulmonary Aspergillosis
ABPA) presenting as the syndrome of severe asthma with fungal
ensitization often with central Bronchiectasis and CPA which in
ost TB patients commonly presents as an Aspergilloma/mycetoma.
n post TB CPA, the fungus, most commonly Aspergillus fumigatus ,
olonizes cavities in the lung left behind by the TB. Precise esti-
ates of the proportion of PTB patients who eventually develop
PA are not available and neither have the risk factors for this
isease been fully identiﬁed. Based on studies conducted in the
nited Kingdom in the 1960’s where rates of radiologically identi-
ed Aspergilloma of up to 22% were found in patients with resid-
al cavities following treatment for TB, Denning et al estimated
hat the incidence of CPA in patients previously treated for PTB
lobally was 372,0 0 0 in 2007. The cumulative ﬁve year prevalence
as estimated to be 1, 174 0 0 0, 852 0 0 0 and 1 372 0 0 0 cases at
5%, 25% and 10% annual attrition rates, respectively implying that
PA post PTB is a major global public health threat [28] . However,
t is evident that the inputs into this modeling need to be updated
ith more recent clinical observations. 
Characteristically CPA, presenting as a simple Aspergilloma will
anifest with the symptoms of prolonged malaise, cough and re-
urrent hemoptysis which can be massive and life threatening. The
iagnosis of CPA is dependent on clinical suspicion, availability and
ccess to chest imaging with plain chest x-rays and CT scans and
vailability of serological testing for Aspergillus precipitins (IgG an-
ibodies). In many parts of the world where TB is endemic these
iagnostic necessities are not routinely available. Similarly, itra-
onazole, which has in recent studies been found to be eﬃcacious
n attenuating the clinical disease associated with CPA [29] , may
lso not be available in low resource, high TB burden settings. The
eﬁnitive treatment of CPA presenting as a simple Aspergilloma
s surgical excision. The availability of cardiothoracic surgical ser-
ices may also be severely limited in low resourced and high TB
ndemic settings. Other long term complications of PTB include airway stenosis
tracheal or bronchial stenosis) and ﬁstulae formations (trachea-
sophageal ﬁstula) all of which threaten life. These complications
ave mostly been reported as case reports or small case series and
herefore their incidence in patients who suffer PTB is currently
nknown. 
hat needs to be done? 
Robust epidemiological studies to determine rates of occurrence
nd risk factors for these complications are lacking which has con-
ributed to the lack of attention given to these problems by na-
ional TB control programs. Of the many possible complications of
TB, COPD, Bronchiectasis and CPA stand out as the most common
roblems that occur in signiﬁcant numbers to require public health
ttention at the global and country level. 
The WHO’s ambitious End TB Strategy approved by all countries
30] targets to reduce TB deaths by 90% in 2030 with intermedi-
te milestones of reduction by 35% in 2020 and 75% in 2025. We
rgue that TB mortality must take into account deaths that occur
ollowing successful bacteriological treatment of PTB which means
hat deaths due to the long term complications of PTB will need
o be factored into the quantiﬁcation of deaths from TB. We there-
ore propose that the public health implications of the long term
omplications of PTB with a special emphasis on COPD, bronchiec-
asis and CPA, should be explored and appropriate public health
easures to deal with them elaborated and implemented. Here
e propose a list of actions that the global TB community in-
luding national TB programmes need to undertake to elaborate
nd evolve appropriate public health programs to confront these
roblems. 
Firstly, we propose that the spectrum and magnitude of post
B chronic lung disease with a special focus on COPD, Bronchiec-
asis and CPA should be clearly established through the conduct of
obust epidemiological studies. Large multi country cohort studies
ay be used for this purpose. This could in the long run help to
stablish the cumulative incidence and the full spectrum of chronic
espiratory disease post PTB and to characterize patients likely to
uffer these clinical problems. Such understanding of the magni-
ude and spectrum of chronic respiratory disease post PTB can be
sed to advocate for resources to manage PTB beyond cure of TB
s currently deﬁned. 
Secondly, we suggest that the minimum set of clinical evalu-
tions and interventions that need to be carried out at the end
f treatment for PTB be deﬁned. As discussed above the current
ractice of using bacteriological clearance of Mycobacterium tuber-
ulosis or completion of treatment as a measure of treatment suc-
ess is likely to be missing a signiﬁcant proportion of patients who
eed to continue to remain in care as a result of the episode of
TB. This evaluation should include assessment of structural and
unctional integrity of the lungs and associated symptoms and
ow these changes are impacting the quality of life of affected
ndividuals. It is also important to assess patients for risk of and
resence of fungal colonization or infection at the end of their
reatment in order to identify those who need additional care for
PA. 
Lastly, we propose that implementation science should be used
o develop and assess the eﬃcacy, effectiveness and costs of pub-
ic health approaches for the delivery of care packages for post
B chronic respiratory disease. These care programs may be mod-
led along those currently elaborated for other chronic respiratory
nd non- respiratory diseases. Lessons learnt from the provision of
hronic care using the Practical Approach to Lung Health (PAL [31]
ay be used to inform the design of care programs for chronic
espiratory disease resulting from PTB. 
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 Conclusion 
Exploring mechanisms to address the long term complications
that follow treatment of pulmonary TB is long overdue and will
signiﬁcantly contribute to the quality of care for TB patients. In
many PTB patients successful completion of TB treatment or bac-
teriological cure is not the end of the need for care. Systematic
generation of data is needed to develop approaches for the pre-
vention, care and treatment of patients with post TB chronic lung
disease. The global TB community cannot afford to continue ignor-
ing this facet of TB care and control and needs to act with urgency
to address what is likely to be a huge public health burden. 
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